Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 19
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease

  • Codony, Sandra|||0000-0003-0539-673X
  • Pont, Caterina|||0000-0001-9118-0892
  • Griñán-Ferré, Christian|||0000-0002-5424-9130
  • Di Pede-Mattatelli, Ania
  • Calvó-Tusell, Carla|||0000-0003-2681-8460
  • Feixas, Ferran|||0000-0001-5147-0000
  • Osuna, Sílvia|||0000-0003-3657-6469
  • Jarné-Ferrer, Júlia
  • Naldi, Marina
  • Bartolini, Manuela|||0000-0002-2890-3856
  • Loza, María Isabel|||0000-0003-4730-0863
  • Brea, José|||0000-0002-5523-1979
  • Pérez, Belén|||0000-0001-5801-1704
  • Bartra, Clara
  • Sanfeliu i Pujol, Coral|||0000-0002-9004-1206
  • Juárez-Jiménez, Jordi|||0000-0003-1464-1397
  • Morisseau, Christophe
  • Hammock, Bruce D.|||0000-0003-1408-8317
  • Pallàs, Mercè|||0000-0003-3095-4254
  • Vázquez, Santiago|||0000-0002-9296-6026
  • Muñoz-Torrero López-Ibarra, Diego|||0000-0002-8140-8555
With innumerable clinical failures of target-specific drug candidates for multifactorial diseases, such as Alzheimer's disease (AD), which remains inefficiently treated, the advent of multitarget drug discovery has brought a new breath of hope. Here, we disclose a class of 6-chlorotacrine (huprine)-TPPU hybrids as dual inhibitors of the enzymes soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE), a multitarget profile to provide cumulative effects against neuroinflammation and memory impairment. Computational studies confirmed the gorge-wide occupancy of both enzymes, from the main site to a secondary site, including a so far non-described AChE cryptic pocket. The lead compound displayed in vitro dual nanomolar potencies, adequate brain permeability, aqueous solubility, human microsomal stability, lack of neurotoxicity, and it rescued memory, synaptic plasticity, and neuroinflammation in an AD mouse model, after low dose chronic oral administration.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The protein aggregation inhibitor YAT2150 has potent antimalarial activity in Plasmodium falciparum in vitro cultures

  • Bouzón-Arnáiz, Inés
  • Avalos-Padilla, Yunuen
  • Biosca, Arnau
  • Caño-Prades, Omar
  • Román-Álamo, Lucía
  • Valle, Javier
  • Andreu Martínez, David
  • Moita, Diana
  • Prudêncio, Miguel
  • Arce, Elsa M.
  • Muñoz-Torrero, Diego
  • Fernàndez Busquets, Xavier
Background: By 2016, signs of emergence of Plasmodium falciparum resistance to artemisinin and partner drugs were detected in the Greater Mekong Subregion. Recently, the independent evolution of artemisinin resistance has also been reported in Africa and South America. This alarming scenario calls for the urgent development of new antimalarials with novel modes of action. We investigated the interference with protein aggregation, which is potentially toxic for the cell and occurs abundantly in all Plasmodium stages, as a hitherto unexplored drug target in the pathogen. Results: Attempts to exacerbate the P. falciparum proteome's propensity to aggregation by delivering endogenous aggregative peptides to in vitro cultures of this parasite did not significantly affect their growth. In contrast, protein aggregation inhibitors clearly reduced the pathogen's viability. One such compound, the bis(styrylpyridinium) salt YAT2150, exhibited potent antiplasmodial activity with an in vitro IC50 of 90 nM for chloroquine- and artemisinin-resistant lines, arresting asexual blood parasites at the trophozoite stage, as well as interfering with the development of both sexual and hepatic forms of Plasmodium. At its IC50, this compound is a powerful inhibitor of the aggregation of the model amyloid β peptide fragment 1-40, and it reduces the amount of aggregated proteins in P. falciparum cultures, suggesting that the underlying antimalarial mechanism consists in a generalized impairment of proteostasis in the pathogen. YAT2150 has an easy, rapid, and inexpensive synthesis, and because it fluoresces when it accumulates in its main localization in the Plasmodium cytosol, it is a theranostic agent. Conclusions: Inhibiting protein aggregation in Plasmodium significantly reduces the parasite's viability in vitro. Since YAT2150 belongs to a novel structural class of antiplasmodials with a mode of action that potentially targets multiple gene products, rapid evolution of resistance to this drug is unlikely to occur, making it a promising compound for the post-artemisinin era., This work was supported by grants (i) PCIN-2017-100, RTI2018-094579-B-I00 and PID2021-128325OB-I00 (XF-B), and SAF2017-82771-R and PID2020-118127RB-I00 (DM-T), funded by Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033 for grants PID2021- and PID2020-), which for grants RTI2018-, PID2021-, and SAF2017- included FEDER funds; (ii) ERA-NET Cofund EURONANOMED (http://euronanomed.net/), grant number 2017-178 (XF-B); and (iii) Generalitat de Catalunya, Spain (http://agaur.gencat.cat/), grant numbers 2017-SGR-908 (XF-B) and 2017-SGR-106 (DM-T). Work at Pompeu Fabra University was supported by the “La Caixa” Banking Foundation (https://fundacionlacaixa.org/, grant HR17-00409), and by grant AGL2017-84097-C2-2-R and the “María de Maeztu” Program for Units of Excellence in R&D from the Spanish Ministry of Science, Innovation and Universities. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Discovery and in vivo proof of concept of a highly potent dual inhibitor of soluble Epoxide Hydrolase and Acetylcholinesterase for the treatment of Alzheimer’s disease

  • Codony, Sandra
  • Pont, Caterina
  • Griñán Ferré, Christian
  • Pede-Mattatelli, Ania di
  • Calvó Tusell, Carla
  • Feixas, Ferrán
  • Osuna, Sílvia
  • Jarné Ferrer, Júlia
  • Naldi, Marina
  • Bartolini, Manuela
  • Loza García, María Isabel
  • Brea Floriani, José Manuel
  • Pérez, Belén
  • Bartra, Clara
  • Sanfeliu, Coral
  • Juárez Jiménez, Jordi
  • Morisseau, Christophe
  • Hammock, Bruce D.
  • Pallàs, Mercè
  • Vázquez, Santiago
  • Muñoz Torrero, Diego
With innumerable clinical failures of target-specific drug candidates for multifactorial diseases, such as Alzheimer’s disease (AD), which remains inefficiently treated, the advent of multitarget drug discovery has brought a new breath of hope. Here, we disclose a class of 6-chlorotacrine (huprine)–TPPU hybrids as dual inhibitors of the enzymes soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE), a multitarget profile to provide cumulative effects against neuroinflammation and memory impairment. Computational studies confirmed the gorge-wide occupancy of both enzymes, from the main site to a secondary site, including a so far non-described AChE cryptic pocket. The lead compound displayed in vitro dual nanomolar potencies, adequate brain permeability, aqueous solubility, human microsomal stability, lack of neurotoxicity, and it rescued memory, synaptic plasticity, and neuroinflammation in an AD mouse model, after low dose chronic oral administration
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

2-(Piperidin-4-yl)acetamides as potent inhibitors of soluble epoxide hydrolase with anti-inflammatory activity

  • Martín López, Juan
  • Codony, Sandra
  • Bartra, Clara
  • Morisseau, Christophe
  • Loza García, María Isabel
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Brea Floriani, José Manuel
  • Vázquez, Santiago
The pharmacological inhibition of soluble epoxide hydrolase (sEH) has been suggested as a potential therapy for the treatment of pain and inflammatory diseases through the stabilization of endogenous epoxyeicosatrienoic acids. Numerous potent sEH inhibitors (sEHI) have been developed, however many contain highly lipophilic substituents limiting their availability. Recently, a new series of benzohomoadamantane-based ureas endowed with potent inhibitory activity for the human and murine sEH was reported. However, their very low microsomal stability prevented further development. Herein, a new series of benzohomoadamantane-based amides were synthetized, fully characterized, and evaluated as sEHI. Most of these amides were endowed with excellent inhibitory potencies. A selected compound displayed anti-inflammatory effects with higher effectiveness than the reference sEHI, TPPU
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease

  • Turcu, Andreea L.
  • Companys Alemany, Júlia
  • Phillips, Matthew B.
  • Patel, Dhilon S.
  • Griñán Ferré, Christian
  • Loza García, María Isabel
  • Brea Floriani, José Manuel
  • Pérez, Belén
  • Soto, David
  • Sureda, Francesc X.
  • Kurnikova, Maria G.
  • Johnson, Jon W.
  • Pallàs, Mercè
  • Vázquez, Santiago
Currently, of the few accessible symptomatic therapies for Alzheimer's disease (AD), memantine is the only N-methyl-d-aspartate receptor (NMDAR) blocker approved by the FDA. This work further explores a series of memantine analogs featuring a benzohomoadamantane scaffold. Most of the newly synthesized compounds block NMDARs in the micromolar range, but with lower potency than previously reported hit IIc, results that were supported by molecular dynamics simulations. Subsequently, electrophysiological studies with the more potent compounds allowed classification of IIc, a low micromolar, uncompetitive, voltage-dependent, NMDAR blocker, as a memantine-like compound. The excellent in vitro DMPK properties of IIc made it a promising candidate for in vivo studies in Caenorhabditis elegans (C. elegans) and in the 5XFAD mouse model of AD. Administration of IIc or memantine improved locomotion and rescues chemotaxis behavior in C. elegans. Furthermore, both compounds enhanced working memory in 5XFAD mice and modified NMDAR and CREB signaling, which may prevent synaptic dysfunction and modulate neurodegenerative progression
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects

  • Pont, Caterina
  • Ginex, Tiziana
  • Griñán Ferré, Christian
  • Scheiner, Matthias
  • Mattellone, Alexia
  • Martínez, Noemí
  • Arce, Elsa M.
  • Soriano Fernández, Yolanda
  • Naldi, Marina
  • Simone, Angela de
  • Barenys, Marta
  • Gómez Catalán, Jesús
  • Pérez, Belén
  • Sabate, Raimon
  • Andrisano, Vincenza
  • Loza García, María Isabel
  • Brea Floriani, José Manuel
  • Bartolini, Manuela
  • Bolognesi, Maria Laura
  • Decker, Michael
  • Pallàs, Mercè
  • Luque, F. Javier
  • Muñoz Torrero, Diego
Starting from six potential hits identified in a virtual screening campaign directed to a cryptic pocket of BACE-1, at the edge of the catalytic cleft, we have synthesized and evaluated six hybrid compounds, designed to simultaneously reach BACE-1 secondary and catalytic sites and to exert additional activities of interest for Alzheimer's disease (AD). We have identified a lead compound with potent in vitro activity towards human BACE-1 and cholinesterases, moderate Aβ42 and tau antiaggregating activity, and brain permeability, which is nontoxic in neuronal cells and zebrafish embryos at concentrations above those required for the in vitro activities. This compound completely restored short- and long-term memory in a mouse model of AD (SAMP8) relative to healthy control strain SAMR1, shifted APP processing towards the non-amyloidogenic pathway, reduced tau phosphorylation, and increased the levels of synaptic proteins PSD95 and synaptophysin, thereby emerging as a promising disease-modifying, cognition-enhancing anti-AD lead
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

From the Design to the In Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis

  • Codony, Sandra
  • Calvó-Tusell, Carla
  • Valverde, Elena
  • Osuna, Sílvia
  • Morisseau, Christophe
  • Loza García, María Isabel
  • Brea Floriani, José Manuel
  • Pérez, Concepción
  • Rodríguez-Franco, María Isabel
  • Pizarro-Delgado, Javier
  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Pallàs, Mercè
  • Sanfeliu, Coral
  • Vázquez-Carrera, Manuel
  • Hammock, Bruce D.
  • Feixas, Ferran
  • Vázquez, Santiago
The pharmacological inhibition of soluble epoxide hydrolase (sEH) is efficient for the treatment of inflammatory and pain-related diseases. Numerous potent sEH inhibitors (sEHIs) present adamantyl or phenyl moieties, such as the clinical candidates AR9281 or EC5026. Herein, in a new series of sEHIs, these hydrophobic moieties have been merged in a benzohomoadamantane scaffold. Most of the new sEHIs have excellent inhibitory activities against sEH. Molecular dynamics simulations suggested that the addition of an aromatic ring into the adamantane scaffold produced conformational rearrangements in the enzyme to stabilize the aromatic ring of the benzohomoadamantane core. A screening cascade permitted us to select a candidate for an in vivo efficacy study in a murine model of cerulein-induced acute pancreatitis. The administration of 22 improved the health status of the animals and reduced pancreatic damage, demonstrating that the benzohomoadamantane unit is a promising scaffold for the design of novel sEHIs.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Soluble Epoxide Hydrolase Inhibition to Face Neuroinflammation in Parkinson’s Disease: A New Therapeutic Strategy

  • Pallàs, Mercè
  • Vázquez, Santiago
  • Sanfeliu, Coral
  • Galdeano, Carles
  • Griñán-Ferré, Christian
© 2020 by the authors., Neuroinflammation is a crucial process associated with the pathogenesis of neurodegenerative diseases, including Parkinson’s disease (PD). Several pieces of evidence suggest an active role of lipid mediators, especially epoxy-fatty acids (EpFAs), in the genesis and control of neuroinflammation; 14,15-epoxyeicosatrienoic acid (14,15-EET) is one of the most commonly studied EpFAs, with anti-inflammatory properties. Soluble epoxide hydrolase (sEH) is implicated in the hydrolysis of 14,15-EET to its corresponding diol, which lacks anti-inflammatory properties. Preventing EET degradation thus increases its concentration in the brain through sEH inhibition, which represents a novel pharmacological approach to foster the reduction of neuroinflammation and by end neurodegeneration. Recently, it has been shown that sEH levels increase in brains of PD patients. Moreover, the pharmacological inhibition of the hydrolase domain of the enzyme or the use of sEH knockout mice reduced the deleterious effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration. This paper overviews the knowledge of sEH and EETs in PD and the importance of blocking its hydrolytic activity, degrading EETs in PD physiopathology. We focus on imperative neuroinflammation participation in the neurodegenerative process in PD and the putative therapeutic role for sEH inhibitors. In this review, we also describe highlights in the general knowledge of the role of sEH in the central nervous system (CNS) and its participation in neurodegeneration. We conclude that sEH is one of the most promising therapeutic strategies for PD and other neurodegenerative diseases with chronic inflammation process, providing new insights into the crucial role of sEH in PD pathophysiology as well as a singular opportunity for drug development, This study was supported by the Ministerio de Economía, Industria y Competitividad (Agencia Estatal de Investigación, AEI) and Fondo Europeo de Desarrollo Regional (MINECO-FEDER) (Projects SAF2017-82771-R, SAF2016-33307, RTI2018-096429-B-100). C.G.-F., S.V., C.S., and M.P. belong to 2017SGR106 (Generalitat de Catalunya)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: In Vivo Evaluation in a Murine Model of Acute Pancreatitis

  • Codony, Sandra
  • Pujol, Eugènia
  • Pizarro, J.
  • Feixas, Ferran
  • Valverde,E.
  • Loza, María Isabel
  • Brea, José Manuel
  • Saez, Elena
  • Oyarzabal, Julen
  • Pineda-Lucena, Antonio
  • Pérez, Belén
  • Pérez, Concepción
  • Rodríguez-Franco, María Isabel
  • Leiva, Rosana
  • Osuna, Sílvia
  • Morissea, Christophe
  • Hammock, Bruce D.
  • Vázquez-Carrera, Manuel
  • Vázquez, Santiago
In vivo pharmacological inhibition of soluble epoxide hydrolase (sEH) reduces inflammatory diseases, including acute pancreatitis (AP). Adamantyl ureas are very potent sEH inhibitors, but the lipophilicity and metabolism of the adamantane group compromise their overall usefulness. Herein, we report that the replacement of a methylene unit of the adamantane group by an oxygen atom increases the solubility, permeability, and stability of three series of urea-based sEH inhibitors. Most of these oxa-analogues are nanomolar inhibitors of both the human and murine sEH. Molecular dynamics simulations rationalize the molecular basis for their activity and suggest that the presence of the oxygen atom on the adamantane scaffold results in active site rearrangements to establish a weak hydrogen bond. The 2-oxaadamantane 22, which has a good solubility, microsomal stability, and selectivity for sEH, was selected for further in vitro and in vivo studies in models of cerulein-induced AP. Both in prophylactic and treatment studies, 22 diminished the overexpression of inflammatory and endoplasmic reticulum stress markers induced by cerulein and reduced the pancreatic damage., This work was funded by the Spanish Ministerio de Economía Industria y Competitividad (grants SAF2017-82771-R to S.V., SAF2015-64146-R, andMICIU/ICTI2017-2020/Referencito M.V.-C., RTI2018-093955-B-C21 to M.I.R.-F., PGC2018-102192-B-I00 to S.O. and RTI2018-101032-J-I00 to F.F.), the CaixaImpulse 2015 Programme, the Spain EIT Health (Proof of concept 2016), the European Regional Development Fund (ERDF),the Xunta de Galicia (GRC2014/011 and ED431C2018-21), the Fundació Bosch i Gimpera, Universitat de Barcelona (F2I grant), the Generalitat de Catalunya (2017 SGR 106, 2017 SGR 124 and 2017 SGR 1707), the Fundacion Fuentes Dutor ́ , the European Research Council (ERC-2015- StG-679001- NetMoDEzyme to S.O.), and the European Community (MSCA-IF-2014-EF-661160-MetAccembly to F.F.). S.C. and E.P. acknowledge PhD fellowships from the Universitat de Barcelona (APIF grants). E.V. and R.L. thank the Institute of Biomedicine of the University of Barcelona (IBUB) and the Spanish Ministerio de Educacion, Cultura y Deporte ́ (FPU grant), respectively, for PhD grants. Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIHNIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We thank Daniel Closa (IIBB−CSIC, Barcelona, Spain) for advice regarding the histological analyses.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer's Disease

  • Griñán-Ferré, Christian
  • Codony, Sandra
  • Pujol, Eugènia
  • Yang, Jun
  • Leiva, Rosana
  • Escolano, Carmen
  • Puigoriol-Illamola, Dolors
  • Companys-Alemany, Júlia
  • Corpas, Rubén
  • Sanfeliu, Coral
  • Pérez, Belén
  • Loza, María Isabel
  • Brea, José Manuel
  • Morisseau, Christophe
  • Hammock, Bruce D.
  • Vázquez, Santiago
  • Pallàs, Mercè
  • Galdeano, Carles
The inhibition of the enzyme soluble epoxide hydrolase (sEH) has demonstrated clinical therapeutic effects in several peripheral inflammatory-related diseases, with 3 compounds in clinical trials. However, the role of this enzyme in the neuroinflammation process has been largely neglected. Herein, we disclose the pharmacological validation of sEH as a novel target for the treatment of Alzheimer's disease (AD). Evaluation of cognitive impairment and pathological hallmarks were used in 2 models of age-related cognitive decline and AD using 3 structurally different and potent sEH inhibitors as chemical probes. sEH is upregulated in brains from AD patients. Our findings supported the beneficial effects of central sEH inhibition, regarding reducing cognitive impairment, neuroinflammation, tau hyperphosphorylation pathology, and the number of amyloid plaques. This study suggests that inhibition of inflammation in the brain by targeting sEH is a relevant therapeutic strategy for AD., This study was supported by the Ministerio de Economía, Industria y Competitividad (Agencia Estatal de Investigación, AEI) and Fondo Europeo de Desarrollo Regional (MINECO-FEDER) (Projects SAF2017-82771, SAF2016-77703, Fundació La Caixa (project CI18-00002) and SAF2015-68749) and Generalitat de Catalunya (2017 SGR 106). S.C. and E.P. thank the Universitat de Barcelona and the Institute of Biomedicine of the Universitat de Barcelona (IBUB), respectively, for PhD grants. R.L. and D.P.-I. thank the Ministerio de Educación, Cultura y Deporte for PhD grants (FPU program). We would also like to thank Xunta de Galicia (ED431C 2018/21) and Ministerio de Economía, Industria y Competitividad (Innopharma Project) and Fondo Europeo de Desarrollo Regional (MINECO-FEDER). This study was also supported, in part, by grants from the National Institute of Environmental Health Sciences (NIEHS), the RIVER Award, NIEHS/R35 ES030443, and NIEHS Superfund Research Program P42 ES004699. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

2-(Piperidin-4-yl)acetamides as Potent Inhibitors of Soluble Epoxide Hydrolase with Anti-Inflammatory Activity

  • Martín-López, Juan
  • Codony, Sandra
  • Bartra Cabré, Clara
  • Morisseau, Christophe
  • Loza, María Isabel
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Brea, José Manuel
  • Vázquez, Santiago
The pharmacological inhibition of soluble epoxide hydrolase (sEH) has been suggested as a potential therapy for the treatment of pain and inflammatory diseases through the stabilization of endogenous epoxyeicosatrienoic acids. Numerous potent sEH inhibitors (sEHI) have been developed, however many contain highly lipophilic substituents limiting their availability. Recently, a new series of benzohomoadamantane-based ureas endowed with potent inhibitory activity for the human and murine sEH was reported. However, their very low microsomal stability prevented further development. Herein, a new series of benzohomoadamantane-based amides were synthetized, fully characterized, and evaluated as sEHI. Most of these amides were endowed with excellent inhibitory potencies. A selected compound displayed anti-inflammatory effects with higher effectiveness than the reference sEHI, TPPU., This research was funded by the Spanish Ministerio de Economía, Industria y Competitividad (Grants SAF2017-82771-R to S.V., PID2019-106285RB-C22 to C.S.), Grant PID2020-118127RB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” to S.V., the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21), the Generalitat de Catalunya (2017 SGR 106, 2017 SGR 124 and 2017 SGR 1707). S.C. acknowledges a PhD fellowship from the Universitat de Barcelona (APIF grant). Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The protein aggregation inhibitor YAT2150 has potent antimalarial activity in Plasmodium falciparum in vitro cultures

  • Bouzón-Arnáiz, I.
  • Avalos-Padilla, Y.
  • Biosca, A.
  • Caño-Prades, O.
  • Román-Álamo, L.
  • Valle, Javier
  • Andreu, David
  • Moita, D.
  • Prudêncio, M.
  • Arce, E. M.
  • Muñoz-Torrero, Diego
  • Fernàndez-Busquets, Xavier
Background: By 2016, signs of emergence of Plasmodium falciparum resistance to artemisinin and partner drugs were detected in the Greater Mekong Subregion. Recently, the independent evolution of artemisinin resistance has also been reported in Africa and South America. This alarming scenario calls for the urgent development of new antimalarials with novel modes of action. We investigated the interference with protein aggregation, which is potentially toxic for the cell and occurs abundantly in all Plasmodium stages, as a hitherto unexplored drug target in the pathogen. Results: Attempts to exacerbate the P. falciparum proteome’s propensity to aggregation by delivering endogenous aggregative peptides to in vitro cultures of this parasite did not significantly affect their growth. In contrast, protein aggregation inhibitors clearly reduced the pathogen’s viability. One such compound, the bis(styrylpyridinium) salt YAT2150, exhibited potent antiplasmodial activity with an in vitro IC of 90 nM for chloroquine- and artemisinin-resistant lines, arresting asexual blood parasites at the trophozoite stage, as well as interfering with the development of both sexual and hepatic forms of Plasmodium. At its IC, this compound is a powerful inhibitor of the aggregation of the model amyloid β peptide fragment 1-40, and it reduces the amount of aggregated proteins in P. falciparum cultures, suggesting that the underlying antimalarial mechanism consists in a generalized impairment of proteostasis in the pathogen. YAT2150 has an easy, rapid, and inexpensive synthesis, and because it fluoresces when it accumulates in its main localization in the Plasmodium cytosol, it is a theranostic agent. Conclusions: Inhibiting protein aggregation in Plasmodium significantly reduces the parasite’s viability in vitro. Since YAT2150 belongs to a novel structural class of antiplasmodials with a mode of action that potentially targets multiple gene products, rapid evolution of resistance to this drug is unlikely to occur, making it a promising compound for the post-artemisinin era., This work was supported by grants (i) PCIN-2017-100, RTI2018-094579-B-I00 and PID2021-128325OB-I00 (XF-B), and SAF2017-82771-R and PID2020-118127RB-I00 (DM-T), funded by Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033 for grants PID2021- and PID2020-), which for grants RTI2018-, PID2021-, and SAF2017- included FEDER funds; (ii) ERA-NET Cofund EURONANOMED (http://euronanomed.net/), grant number 2017-178 (XF-B); and (iii) Generalitat de Catalunya, Spain (http://agaur.gencat.cat/), grant numbers 2017-SGR-908 (XF-B) and 2017-SGR-106 (DM-T). Work at Pompeu Fabra University was supported by the “La Caixa” Banking Foundation (https://fundacionlacaixa.org/, grant HR17-00409), and by grant AGL2017-84097-C2-2-R and the “María de Maeztu” Program for Units of Excellence in R&D from the Spanish Ministry of Science, Innovation and Universities.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synthesis, in vitro profiling and in vivo evaluation of benzohomoadamantane-based ureas for visceral pain: a new indication for soluble epoxide hydrolase inhibitors

  • Codony, Sandra
  • Entrena, José M.
  • Calvó-Tusell, Carla
  • Osuna, Sílvia
  • Jora, Beatrice
  • González-Cano, Rafael
  • Corpas, Rubén
  • Morisseau, Christophe
  • Pérez, Belén
  • Barniol-Xicota, Marta
  • Griñán-Ferré, Christian
  • Pérez, Concepción
  • Rodríguez-Franco, María Isabel
  • Martínez, Antón L.
  • Loza, María Isabel
  • Pallàs, Mercè
  • Verhelst, Steven H. L.
  • Sanfeliu, Coral
  • Feixas, Ferran
  • Hammock, Bruce D.
  • Brea, José Manuel
  • Cobos, Enrique J.
  • Vázquez, Santiago
The soluble epoxide hydrolase (sEH) has been suggested as a pharmacological target for the treatment of several diseases, including pain-related disorders. Herein, we report further medicinal chemistry around new benzohomoadamantane-based sEH inhibitors (sEHI) in order to improve the drug metabolism and pharmacokinetics properties of a previous hit. After an extensive in vitro screening cascade, molecular modeling, and in vivo pharmacokinetics studies, two candidates were evaluated in vivo in a murine model of capsaicin-induced allodynia. The two compounds showed an anti-allodynic effect in a dose-dependent manner. Moreover, the most potent compound presented robust analgesic efficacy in the cyclophosphamide-induced murine model of cystitis, a well-established model of visceral pain. Overall, these results suggest painful bladder syndrome as a new possible indication for sEHI, opening a new range of applications for them in the visceral pain field., This work was funded by the Spanish Ministerio de Economía, Industria y Competitividad (grants SAF2017-82771-R to S.V., RTI2018-093955-B-C21 to M.I.R.-F., PGC2018-102192-B-I00 to S.O. and RTI2018-101032-J-I00 to F.F.), the Spanish MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” (Grant PID2020-118127RB-I00 to S.V. and Grant PID2019-106285RB to M.P. and C.S.) funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21), the Fundació Bosch i Gimpera, Universitat de Barcelona (F2I grant), the Generalitat de Catalunya (2017 SGR 106 and 2017 SGR 1707), the European Research Council (ERC-2015-StG-679001-NetMoDEzyme to S.O.), and the European Community (MSCA-IF-2014-EF661160-MetAccembly to F.F.). S.C. acknowledges a PhD fellowship from the Universitat de Barcelona (APIF grant) and the Spanish Society of Medicinal Chemistry (SEQT) and Lilly for an “Award for Novel Researchers in the Discovery and Development of New Drugs”. M.B.X. acknowledges FWO for a post-doctoral fellowship (no. 12Y0720N). S.H.L.V. acknowledges the Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen, the Regierende Bürgermeister von Berlin, and the Bundesministerium für Bildung und Forschung. F.F. acknowledges Spanish MICINN for a Ramón y Cajal fellowship (RYC2020-029552-I). Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease

  • Codony, Sandra
  • Pont, Caterina
  • Griñán-Ferré, Christian
  • Di Pede-Mattatelli, Ania
  • Calvó-Tusell, Carla
  • Feixas, Ferran
  • Osuna, Sílvia
  • Jarné-Ferrer, Júlia
  • Naldi, Marina
  • Bartolini, Manuela
  • Loza, María Isabel
  • Brea, José Manuel
  • Pérez, Belén
  • Bartra Cabré, Clara
  • Sanfeliu, Coral
  • Juárez-Jiménez, Jordi
  • Morisseau, Christophe
  • Hammock, Bruce D.
  • Pallàs, Mercè
  • Vázquez, Santiago
  • Muñoz-Torrero, Diego
With innumerable clinical failures of target-specific drug candidates for multifactorial diseases, such as Alzheimer's disease (AD), which remains inefficiently treated, the advent of multitarget drug discovery has brought a new breath of hope. Here, we disclose a class of 6-chlorotacrine (huprine)-TPPU hybrids as dual inhibitors of the enzymes soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE), a multitarget profile to provide cumulative effects against neuroinflammation and memory impairment. Computational studies confirmed the gorge-wide occupancy of both enzymes, from the main site to a secondary site, including a so far non-described AChE cryptic pocket. The lead compound displayed in vitro dual nanomolar potencies, adequate brain permeability, aqueous solubility, human microsomal stability, lack of neurotoxicity, and it rescued memory, synaptic plasticity, and neuroinflammation in an AD mouse model, after low dose chronic oral administration., This work was supported by grants PID2020-118127RB-I00, SAF2017-82771-R, PID2020-115683GA-I00, PGC2018- 102192-B-I00, PID2019-106285RB, and RTI2018-101032-JI00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, ED431C 2018/21 and ED431G 2019/02 from Xunta de Galicia, and 2017SGR106, 2017SGR1707, and 2019LLAV00017 from AGAUR. Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Fellowships from Ministerio de Educación, Cultura y Deporte to C.P. (FPU15/01131), from the University of Barcelona to S.C., and a starting grant from the European Research Council (ERC-2015-StG-679001- NetMoDEzyme) to S.O. are gratefully acknowledged. We thank Ms. Cecilia Mariani for technical assistance in the assays with mAChE., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

From the Design to the In Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis

  • Codony, Sandra
  • Calvó-Tusell, Carla
  • Valverde, Elena
  • Osuna, Sílvia
  • Morisseau, Christophe
  • Loza, M. Isabel
  • Brea, José
  • Pérez, Concepción
  • Rodríguez-Franco, María Isabel
  • Pizarro-Delgado, Javier
  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Pallàs, Mercè
  • Sanfeliu, Coral
  • Vázquez-Carrera, Manuel
  • Hammock, Bruce D.
  • Feixas, Ferran
  • Vázquez, Santiago
The pharmacological inhibition of soluble epoxide hydrolase (sEH) is efficient for the treatment of inflammatory and pain-related diseases. Numerous potent sEH inhibitors (sEHIs) present adamantyl or phenyl moieties, such as the clinical candidates AR9281 or EC5026. Herein, in a new series of sEHIs, these hydrophobic moieties have been merged in a benzohomoadamantane scaffold. Most of the new sEHIs have excellent inhibitory activities against sEH. Molecular dynamics simulations suggested that the addition of an aromatic ring into the adamantane scaffold produced conformational rearrangements in the enzyme to stabilize the aromatic ring of the benzohomoadamantane core. A screening cascade permitted us to select a candidate for an in vivo efficacy study in a murine model of cerulein-induced acute pancreatitis. The administration of 22 improved the health status of the animals and reduced pancreatic damage, demonstrating that the benzohomoadamantane unit is a promising scaffold for the design of novel sEHIs., This work was funded by the Spanish Ministerio de Economía, Industria y Competitividad (grants SAF2017-82771-R to S.V., RTI2018-093999-B-100 to M. V.-C., RTI2018-093955-B-C21 to M.I.R.-F., SAF2016-77703-C2 to M.P. and C.S., PGC2018- 102192-B-I00 to S.O. and RTI2018-101032-J-I00 to F.F.), the Spain EIT Health (Proof of concept 2016), the European Regional Development Fund (ERDF), the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21), the Fundació Bosch i Gimpera, Universitat de Barcelona (F2I grant), the Generalitat de Catalunya (2017 SGR 106, 2017 SGR 124 and 2017 SGR 1707), the European Research Council (ERC-2015-StG-679001-Net- MoDEzyme to S.O.), and the European Community (MSCA-IF- 2014-EF-661160-MetAccembly to F.F.). S.C. and E.V. acknowledge the PhD fellowships from the Universitat de Barcelona (APIF grant) and the Institute of Biomedicine of the University of Barcelona (IBUB), respectively. Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The protein aggregation inhibitor YAT2150 has potent antimalarial activity in Plasmodium falciparum in vitro cultures

  • Bouzón-Arnáiz, Inés
  • Avalos-Padilla, Yunuen
  • Biosca, Arnau
  • Caño-Prades, Omar
  • Román-Álamo, Lucía
  • Valle, Javier
  • Andreu Martínez, David
  • Moita, Diana
  • Prudêncio, Miguel
  • Arce, Elsa M.
  • Muñoz-Torrero, Diego
  • Fernàndez Busquets, Xavier
Background: By 2016, signs of emergence of Plasmodium falciparum resistance to artemisinin and partner drugs were detected in the Greater Mekong Subregion. Recently, the independent evolution of artemisinin resistance has also been reported in Africa and South America. This alarming scenario calls for the urgent development of new antimalarials with novel modes of action. We investigated the interference with protein aggregation, which is potentially toxic for the cell and occurs abundantly in all Plasmodium stages, as a hitherto unexplored drug target in the pathogen. Results: Attempts to exacerbate the P. falciparum proteome's propensity to aggregation by delivering endogenous aggregative peptides to in vitro cultures of this parasite did not significantly affect their growth. In contrast, protein aggregation inhibitors clearly reduced the pathogen's viability. One such compound, the bis(styrylpyridinium) salt YAT2150, exhibited potent antiplasmodial activity with an in vitro IC50 of 90 nM for chloroquine- and artemisinin-resistant lines, arresting asexual blood parasites at the trophozoite stage, as well as interfering with the development of both sexual and hepatic forms of Plasmodium. At its IC50, this compound is a powerful inhibitor of the aggregation of the model amyloid β peptide fragment 1-40, and it reduces the amount of aggregated proteins in P. falciparum cultures, suggesting that the underlying antimalarial mechanism consists in a generalized impairment of proteostasis in the pathogen. YAT2150 has an easy, rapid, and inexpensive synthesis, and because it fluoresces when it accumulates in its main localization in the Plasmodium cytosol, it is a theranostic agent. Conclusions: Inhibiting protein aggregation in Plasmodium significantly reduces the parasite's viability in vitro. Since YAT2150 belongs to a novel structural class of antiplasmodials with a mode of action that potentially targets multiple gene products, rapid evolution of resistance to this drug is unlikely to occur, making it a promising compound for the post-artemisinin era., This work was supported by grants (i) PCIN-2017-100, RTI2018-094579-B-I00 and PID2021-128325OB-I00 (XF-B), and SAF2017-82771-R and PID2020-118127RB-I00 (DM-T), funded by Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033 for grants PID2021- and PID2020-), which for grants RTI2018-, PID2021-, and SAF2017- included FEDER funds; (ii) ERA-NET Cofund EURONANOMED (http://euronanomed.net/), grant number 2017-178 (XF-B); and (iii) Generalitat de Catalunya, Spain (http://agaur.gencat.cat/), grant numbers 2017-SGR-908 (XF-B) and 2017-SGR-106 (DM-T). Work at Pompeu Fabra University was supported by the “La Caixa” Banking Foundation (https://fundacionlacaixa.org/, grant HR17-00409), and by grant AGL2017-84097-C2-2-R and the “María de Maeztu” Program for Units of Excellence in R&D from the Spanish Ministry of Science, Innovation and Universities. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pentafluorosulfanyl-containing triclocarban analogs with potent antimicrobial activity

  • Pujol Bech, Eugenia|||0000-0003-1941-0539
  • Blanco-Cabra, Núria
  • Julián, Esther|||0000-0002-6558-3978
  • Leiva, Rosana
  • Torrents, Eduard|||0000-0002-3010-1609
  • Vázquez, Santiago|||0000-0002-9296-6026
Concerns have been raised about the long-term accumulating effects of triclocarban, a polychlorinated diarylurea widely used as an antibacterial soap additive, in the environment and in human beings. Indeed, the Food and Drug Administration has recently banned it from personal care products. Herein, we report the synthesis, antibacterial activity and cytotoxicity of novel N,N'-diarylureas as triclocarban analogs, designed by reducing one or more chlorine atoms of the former and/or replacing them by the novel pentafluorosulfanyl group, a new bioisostere of the trifluoromethyl group, with growing importance in drug discovery. Interestingly, some of these pentafluorosulfanyl-bearing ureas exhibited high potency, broad spectrum of antimicrobial activity against Gram-positive bacterial pathogens, and high selectivity index, while displaying a lower spontaneous mutation frequency than triclocarban. Some lines of evidence suggest a bactericidal mode of action for this family of compounds.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clock/Sleep-Dependent Learning and Memory in Male 3xTg-AD Mice at Advanced Disease Stages and Extrinsic Effects of Huprine X and the Novel Multitarget Agent AVCRI104P3

  • Gimenez-Llort, Lydia|||0000-0002-4091-489X
  • Santana-Santana, Mikel
  • Ratia, Míriam
  • Pérez, Belén|||0000-0001-5801-1704
  • Camps García, Pelayo|||0000-0002-9633-3525
  • Muñoz-Torrero López-Ibarra, Diego|||0000-0002-8140-8555
  • Badía, A. (Albert)
  • Clos Guillen, Maria Victoria|||0000-0002-7389-3351
A new hypothesis highlights sleep-dependent learning/memory consolidation and regards the sleep-wake cycle as a modulator of β-amyloid and tau Alzheimer's disease (AD) pathologies. Sundowning behavior is a common neuropsychiatric symptom (NPS) associated with dementia. Sleep fragmentation resulting from disturbances in sleep and circadian rhythms in AD may have important consequences on memory processes and exacerbate the other AD-NPS. The present work studied the effect of training time schedules on 12-month-old male 3xTg-AD mice modeling advanced disease stages. Their performance in two paradigms of the Morris water maze for spatial-reference and visual-perceptual learning and memory were found impaired at midday, after 4 h of non-active phase. In contrast, early-morning trained littermates, slowing down from their active phase, exhibited better performance and used goal-directed strategies and non-search navigation described for normal aging. The novel multitarget anticholinesterasic compound AVCRI104P3 (0.6 µmol·kg-1, 21 days i.p.) exerted stronger cognitive benefits than its in vitro equipotent dose of AChEI huprine X (0.12 μmol·kg-1, 21 days i.p.). Both compounds showed streamlined drug effectiveness, independently of the schedule. Their effects on anxiety-like behaviors were moderate. The results open a question of how time schedules modulate the capacity to respond to task demands and to assess/elucidate new drug effectiveness.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Synthesis, In Vitro Profiling, and In Vivo Evaluation of Benzohomoadamantane-Based Ureas for Visceral Pain, A New Indication for Soluble Epoxide Hydrolase Inhibitors

  • Codony, Sandra|||0000-0003-0539-673X
  • Entrena, José M.|||0000-0002-4319-746X
  • Calvó-Tusell, Carla|||0000-0003-2681-8460
  • Jora, Beatrice
  • González-Cano, Rafael|||0000-0002-9657-4521
  • Osuna, Sílvia|||0000-0003-3657-6469
  • Corpas, Rubén|||0000-0002-7051-1493
  • Morisseau, Christophe
  • Pérez, Belén|||0000-0001-5801-1704
  • Barniol-Xicota, Marta|||0000-0001-7957-2199
  • Griñán-Ferré, Christian|||0000-0002-5424-9130
  • Pérez, Concepción
  • Rodríguez-Franco, María Isabel|||0000-0002-6500-792X
  • Martínez, Antón L.|||0000-0002-1595-3459
  • Loza, María Isabel|||0000-0003-4730-0863
  • Pallàs, Mercè|||0000-0003-3095-4254
  • Verhelst, Steven H. L.|||0000-0002-7400-1319
  • Sanfeliu i Pujol, Coral|||0000-0002-9004-1206
  • Feixas, Ferran|||0000-0001-5147-0000
  • Hammock, Bruce D.|||0000-0003-1408-8317
  • Brea, José|||0000-0002-5523-1979
  • Cobos, Enrique J.
  • Vázquez, Santiago|||0000-0002-9296-6026
The soluble epoxide hydrolase (sEH) has been suggested as a pharmacological target for the treatment of several diseases, including pain-related disorders. Herein, we report further medicinal chemistry around new benzohomoadamantane-based sEH inhibitors (sEHI) in order to improve the drug metabolism and pharmacokinetics properties of a previous hit. After an extensive in vitro screening cascade, molecular modeling, and in vivo pharmacokinetics studies, two candidates were evaluated in vivo in a murine model of capsaicin-induced allodynia. The two compounds showed an anti-allodynic effect in a dose-dependent manner. Moreover, the most potent compound presented robust analgesic efficacy in the cyclophosphamide-induced murine model of cystitis, a well-established model of visceral pain. Overall, these results suggest painful bladder syndrome as a new possible indication for sEHI, opening a new range of applications for them in the visceral pain field.